(3) The Part B IPI Model

The Certara Market Access Channel

#Science #Certara Evidence & Access #Certara Evidence

38:30

Chef Shuai Wang was the runner-up on the 22nd season of Bravo’s Top Chef and is the force behind two standout restaurants in Charleston, South Carolina—Jackrabbit Filly and King BBQ—where he brings together the flavors of his childhood in Beijing and the spirit of the South in some pretty unforgettable ways. He grew up just a short walk from Tiananmen Square, in a tiny home with no electricity or running water, where his grandmother often cooked over charcoal. Later, in Queens, New York, his mom taught herself to cook—her first dishes were a little salty, but they were always made with love. And somewhere along the way, Shuai learned that cooking wasn’t just about food—it was about taking care of people. After years working in New York kitchens, he made his way to Charleston and started building something that feels entirely his own. Today, we’re talking about how all those experiences come together on the plate, the family stories behind his cooking, and what it’s been like to share that journey on national TV. Learn more about your ad choices. Visit podcastchoices.com/adchoices…

7 years ago 26:06

MP3•Episode home

In this episode, we're dissecting the US Administrations initiative to overhaul Medicare Part B drug reimbursement, incorporating international reference pricing. Experts on call Ulrich Neumann, Sr. Director, US Access ulrich.neumann@certara.com Additional notes: - We referenced the Implications of Pricing on Innovation which is thoroughly discussed in this article by USC's Darius Lakdawalla Lakdawalla, Darius N. 2018. "Economics of the Pharmaceutical Industry." Journal of Economic Literature, 56 (2): 397-449. DOI: 10.1257/jel.20161327 --- Send in a voice message: https://podcasters.spotify.com/pod/show/market-access/message

4 episodes

(3) The Part B IPI Model

The Certara Market Access Channel

published 7 years ago

MP3•Episode home

4 episodes

#Science #Certara Evidence & Access #Certara Evidence

All episodes

1
(4) Policy Briefing: A new agenda for CMS, the Biden White House, and a Democratic Congress 20:34

4 years ago20:34

20:34

We're finally back with a new season for the Radar Podcast, pharma's flagship intelligence briefing on all things market access, real-world evidence, and payer strategy. This program is brought to you by the experts in Certara's global Evidence & Access practice. In this episode, we're discussing the Biden administration's policy positions, the fate of Trump-era CMS proposals, and what the new majority in the 117th Congress will mean for the biopharma industry. Your host for this week is Max Goldstein, Director of Business Development, speaking to Ulrich Neumann, Senior Director, Access and Commercial Strategy. For any questions on the topics discussed today, please contact ulrich.neumann@certara.com or download our latest whitepapers here: https://www.certara.com/evidence-access/us-managed-markets/key-trends-us-specialty/ --- Send in a voice message: https://podcasters.spotify.com/pod/show/market-access/message…

1
(3) The Part B IPI Model 26:06

7 years ago26:06

26:06

1
(2) IDN and Pharma Collaborations 44:05

7 years ago44:05

44:05

Listen in for this stakeholder panel on strategic collaborations with hospital & provider systems, IDNs and ACOs to bring value-based care to patients. Experts on call Shontelle Dodson, SVP, Astellas Matt Portch, VP Sunovion, Gergana Zlateva, VP Pfizer, Terrill Jordan, CEO of the RCCA provider network Ulrich Neumann, Sr. Director, Head US Access, Certara (ulrich.neumann@certara.com) --- Send in a voice message: https://podcasters.spotify.com/pod/show/market-access/message…

1
(1): Outcomes Based Agreements: Deal or No Deal 1:07:38

7 years ago1:07:38